The Obesity Pill That Could Crash Big Pharma's Party

Those numbers are eye-watering, even by GLP-1 standards. For context, GLP-1 drugs (the class that includes Ozempic and Mounjaro) are known for causing stomach issues. That's basically part of the deal. But these rates are on the high side.

The silver lining: despite all that GI distress, only about 3-4% of patients actually quit the trial because of side effects. That's surprisingly low given the nausea rates. It suggests most patients powered through, possibly because the weight loss was worth it to them. Kailera is also working on a pH-modulated formulation (using sodium carbonate to slow how the drug dissolves) designed to reduce those peak-related stomach problems.

Why This Matters Beyond China

Kailera isn't just a Chinese pharma story dressed up in a Western wrapper. It's a $1.0 billion-funded biotech backed by Bain Capital, Atlas Venture, and RTW Investments, built specifically to take Hengrui's metabolic drugs global.

The partnership structure is massive. Hengrui keeps the rights in Greater China. Kailera gets exclusive rights everywhere else. The total deal is valued at up to $6 billion when you stack up the upfront payment (around $100-110 million), clinical milestones ($200 million), and sales-based milestones ($5.7 billion).

Kailera is already running a global Phase 2 obesity trial with higher doses of the pill (up to 360 mg over 44 weeks), with data expected in 2027. Higher doses could mean more weight loss, which would be critical for competing with established players.

The Oral GLP-1 Race Is Getting Crowded

The obesity pill market in 2026 looks like the streaming wars of 2020: everyone wants in, and nobody's sure who'll win.

Novo Nordisk launched its oral version of Wegovy (a peptide-based pill requiring fasting before you take it) in January 2026. Eli Lilly's Foundayo (orforglipron), the first small-molecule oral GLP-1, got FDA approval in April 2026. Those two are currently splitting the market.

But the second wave is coming fast. Roche's CT-996 showed approximately 7.3% weight loss at 4 weeks in Phase 1 testing. AstraZeneca launched a full Phase 3 program for elecoglipron in June 2026, with the EMBOLD obesity master protocol formally starting in July 2026. Analysts expect six to eight oral GLP-1 drugs to be approved globally by 2030.

Kailera's HRS-7535 sits in an interesting spot. Its 10-11% weight loss over roughly a year is competitive with existing injectable GLP-1s, but it trails the injectable heavy hitters. Kailera's own injectable drug, KAI-9531 (a dual GLP-1/GIP agonist like Mounjaro), showed about 18-19% weight loss in its China Phase 3 trial. That's the asset Wall Street is really watching.

The oral pill is more of a strategic play: a convenient, no-needle option for patients who want something simpler, even if it means slightly less weight loss.

What Happens Next

In China, Hengrui is preparing to file for diabetes approval first, with an obesity filing likely following in 2027 once the remaining data are finalized. For the injectable KAI-9531, a China obesity filing is coming even sooner.

Globally, the oral pill is still a few years behind the injectable. Kailera's Phase 2 data won't land until 2027, and a global Phase 3 hasn't been announced yet. Think 2028 or later for a potential U.S. or European filing.

But that timeline isn't necessarily a weakness. The oral obesity market is projected to hit $22 billion by 2030, capturing about a quarter of all weight-loss drug sales. Even capturing a slice of that pie would justify Kailera's existence.

The real question is whether the GI side effects can be tamed with better formulations and dosing strategies. If Kailera can keep the weight loss while calming patients' stomachs, it has a genuine shot at crashing the Lilly-Novo duopoly.

If not, this becomes another story about a drug that worked on paper but couldn't survive first contact with real-world patients. The next 18 months will tell us which story we're reading.